Andy Partridge is Chief Commercial Officer at GRAIL. He brings more than 25 years of global sales and marketing experience leading global commercial launches across multiple indications, including oncology, hematology and rare diseases. Prior to joining GRAIL, he served as Chief Commercial Officer at Turning Point Therapeutics, building out the commercial team for the launches of oral oncology agents for rare lung cancer mutations. As Senior Vice President and Head of North American Commercial Operations at Vertex Pharmaceuticals, he built the team to successfully launch multiple cystic fibrosis therapies and new indications, creating a multi-billion dollar franchise and transforming patients’ lives. He also served in sales and marketing roles at Schering-Plough, Roche, and Amgen. Andy started his business career in a sales role for Boehringer-Mannheim Diagnostics after earning a Higher National Diploma in Medical Laboratory Sciences from Birmingham City University in the U.K. and working as a Medical Laboratory Scientist in a busy city center academic hospital.